ARVN vs GLUE
ARVN: Arvinas is a pioneer in targeted protein degradation, utilizing its PROTAC platform to develop small molecule therapeutics that eliminate disease-causing proteins. GLUE: Monte Rosa Therapeutics develops molecular glue degraders—a novel class of protein degradation drugs targeting historically undruggable proteins through its proprietary QuEEN discovery platform.
Side-by-side fundamentals
| Metric | ARVN | GLUE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $8.26 | $23.79 | |
| Market cap as of 2026-07-23 | $536M | $2.0B | |
| PEG as of 2026-07-23 | -0.01 | n/a | |
| Net margin as of 2026-07-23 | -247.5% | -302.7% | ARVN higher |
| Operating margin as of 2026-07-23 | -283.8% | -345.2% | ARVN higher |
| ROE as of 2026-07-23 | -44.4% | -41.0% | GLUE higher |
| ROA as of 2026-07-23 | -28.4% | -25.9% | GLUE higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | GLUE lower |
| Revenue growth (YoY) as of 2026-07-23 | -79.1% | -73.1% | GLUE higher |
| Revenue CAGR (3y) SEC XBRL | +26.0% | n/a | |
| Beta as of 2026-07-23 | 1.73 | 1.49 | |
| 1-year return as of 2026-07-22 close | +9.8% | +305.3% | GLUE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.